MedTrace Logo

Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor

NCT02297971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2015-09-29

No results posted yet for this study

Summary

When ticagrelor should be discontinued prior to elective surgery is unclear. The risks of bleeding when it is continued peri-operatively have to be weighed against the risk of coronary artery thrombosis when stopped. This study aims to assess coagulation and thrombocyte function every other day in patients who are taking ticagrelor after coronary artery stents and discontinue therapy at the end of one year.

Conditions

  • PCI
  • Coronary Stents

Sponsors & Collaborators

  • Örebro University, Sweden

    lead OTHER

Principal Investigators

  • Anil Gupta, MD, PhD · Örebro University, Sweden

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02297971 on ClinicalTrials.gov